Canaccord raised the firm’s price target on AtriCure to $52 from $50 and keeps a Buy rating on the shares. The firm updated its model following the release of its preliminary Q4 and 2023 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ATRC:
